Travere Therapeutics's market cap is currently $1.97B. The company's EPS TTM is $-4.557; its P/E ratio is ―; Travere Therapeutics is scheduled to report earnings on March 3, 2025, and the estimated EPS forecast is $-0.56. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 145.24M	$ 212.02M	$ 227.49M	$ 198.32M	$ 175.34M
Gross Profit	$ 133.79M	$ 204.43M	$ 220.71M	$ 192.19M	$ 170.10M
Operating Income	$ -376.74M	$ -251.56M	$ -139.50M	$ -75.38M	$ -99.81M
EBITDA	$ -326.25M	$ -299.42M	$ -186.68M	$ -143.95M	$ -107.21M
Net Income	$ -111.40M	$ -278.48M	$ -180.09M	$ -169.43M	$ -146.43M
Balance Sheet
Cash & Short-Term Investments	$ 566.85M	$ 450.25M	$ 552.88M	$ 361.59M	$ 398.52M
Total Assets	$ 788.91M	$ 672.59M	$ 776.63M	$ 607.44M	$ 604.80M
Total Debt	$ 404.78M	$ 407.49M	$ 261.99M	$ 215.34M	$ 204.86M
Net Debt	$ 346.61M	$ 345.80M	$ 96.23M	$ 130.57M	$ 142.43M
Total Liabilities	$ 588.10M	$ 629.73M	$ 474.52M	$ 396.23M	$ 383.60M
Stockholders' Equity	$ 200.81M	$ 42.85M	$ 302.11M	$ 211.21M	$ 221.20M
Cash Flow
Free Cash Flow	$ -322.28M	$ -214.85M	$ -38.94M	$ -162.59M	$ -73.78M
Operating Cash Flow	$ -280.02M	$ -186.29M	$ -14.79M	$ -42.74M	$ -58.21M
Investing Cash Flow	$ 55.78M	$ -32.55M	$ -137.62M	$ -61.33M	$ 19.86M
Financing Cash Flow	$ 218.75M	$ 117.57M	$ 231.68M	$ 127.71M	$ -2.08M

Currency in USD

Travere Therapeutics Earnings and Revenue History

Income Statement >

Travere Therapeutics Debt to Assets

Balance Sheet >

Travere Therapeutics Cash Flow

Cash Flow >

Travere Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing